Sutro Biopharma, Inc.
Sutro Biopharma, Inc. (STRO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · STRO · as of Jun 9, 2026
Key Statistics
Explore Sutro Biopharma, Inc. Data
stro stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 20 · Buy rate: 90.0%
The STRO analyst consensus is Buy, based on ratings from 20 Wall Street analysts over the past 3 months. The average 12-month price target is $51.80, representing +103.86% upside from the current price of $25.41.
Competitors & Peers
stro competitorsSTRO
ADVM
ARTV
CNTB
DTIL
GUTSStock Performance
Full HistoryAbout Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-…
what is sutro biopharma, inc. · stro stock overview · sutro biopharma, inc. company profile · who is sutro biopharma, inc. ceo · stro NASDAQ · sutro biopharma, inc. headquarters · sutro biopharma, inc. business segments
About Stock Overview & Key Data
Sutro Biopharma, Inc. (STRO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 27, 2018. As of the latest trading session, STRO stock price is $25.41, with a market capitalization of $245.9M. The stock has returned +207.26% over the past 12 months and +119.62% year-to-date.
According to 20 Wall Street analysts, the consensus rating for Sutro Biopharma, Inc. stock is Buy, with an average 12-month price target of $51.80. In fiscal year 2025, Sutro Biopharma, Inc. reported revenue of $102.5M and net income of -$191.1M. For detailed data — including Sutro Biopharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Sutro Biopharma, Inc. (STRO) stock price is $25.41. The stock is traded on NASDAQ under the ticker symbol STRO. The 52-week range is $6.70 – $43.85.